Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Jul 22, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed July 22, 2026
Period End
July 22, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed July 22, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced in a Form 8-K dated July 22, 2026 that the U.S. FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of autosomal dominant hypocalcemia type 1 (ADH1).

The FDA assigned a PDUFA target action date of May 8, 2027, and the company says it is prepared to launch encaleret upon approval, which it describes as a potential blockbuster opportunity. The FDA also indicated it is not currently planning to hold an advisory committee meeting on the application. The company states that the Phase 3 CALIBRATE trial in ADH1 achieved all pre-specified primary and key secondary efficacy endpoints, with additional results presented at the European Congress of Endocrinology 2026 and the Endocrine Society 2026 annual meeting.

BridgeBio says encaleret normalized key markers of calcium-sensing receptor-driven disease biology without the need for calcium and vitamin D supplements, and reports a favorable safety and tolerability profile. The company also cites claims data showing more than 2,100 U.S. individuals diagnosed with autosomal dominant hypocalcemia since October 2023 as of April 2026.

BridgeBio also stated it is enrolling CALIBRATE-PEDS, a registrational Phase 2/3 study in pediatric ADH1, intends to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, and plans to initiate the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism later this summer. The filing itself is an Item 8.01 disclosure that incorporates the press release by reference as Exhibit 99.1.

Key Highlights

  1. FDA accepted the New Drug Application for encaleret for ADH1, with a PDUFA target action date of May 8, 2027.
  2. The FDA is not currently planning to hold an advisory committee meeting on the application.
  3. The company describes encaleret as a potential blockbuster opportunity and says it is prepared to launch upon approval.
  4. The Phase 3 CALIBRATE trial reportedly met all pre-specified primary and key secondary efficacy endpoints.
  5. Encaleret is described as having a favorable safety and tolerability profile and as normalizing key disease markers without calcium and vitamin D supplements.
  6. BridgeBio plans an EMA Marketing Authorization Application in the second half of 2026 and is enrolling the pediatric CALIBRATE-PEDS study.
  7. The RECLAIM-HP Phase 3 study in chronic hypoparathyroidism is planned to begin later this summer.

Frequently Asked Questions

  1. What regulatory milestone did BridgeBio announce?

    The FDA accepted the New Drug Application for encaleret for the treatment of individuals with autosomal dominant hypocalcemia type 1 (ADH1) and assigned a PDUFA target action date of May 8, 2027.

  2. Will there be an advisory committee meeting for encaleret?

    The FDA notified the company that it is not currently planning to hold an advisory committee meeting to discuss the application.

  3. What clinical data does the company cite for encaleret?

    The company says the Phase 3 CALIBRATE trial achieved all pre-specified primary and key secondary efficacy endpoints, with data showing simultaneous restoration of blood and urine calcium and restoration of physiologic parathyroid hormone production, presented at ECE 2026 and ENDO 2026.

  4. What are the company's next development and filing steps?

    BridgeBio is enrolling the registrational Phase 2/3 CALIBRATE-PEDS study in pediatric ADH1, intends to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, and plans to initiate the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism later this summer.

  5. How large is the addressable patient population according to the filing?

    The company cites claims data showing over 2,100 individuals diagnosed in the U.S. with autosomal dominant hypocalcemia since October 2023, as of April 2026.